243 related articles for article (PubMed ID: 23519387)
1. Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals.
Dominguez M; Perez JA; Patel CB
Methodist Debakey Cardiovasc J; 2013; 9(1):49-53. PubMed ID: 23519387
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Annane D; Decaux G; Smith N;
Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376
[TBL] [Abstract][Full Text] [Related]
5. Conivaptan for hyponatremia in the neurocritical care unit.
Wright WL; Asbury WH; Gilmore JL; Samuels OB
Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.
Koren MJ; Hamad A; Klasen S; Abeyratne A; McNutt BE; Kalra S
Am J Health Syst Pharm; 2011 May; 68(9):818-27. PubMed ID: 21515866
[TBL] [Abstract][Full Text] [Related]
7. Current treatment practice and outcomes. Report of the hyponatremia registry.
Greenberg A; Verbalis JG; Amin AN; Burst VR; Chiodo JA; Chiong JR; Dasta JF; Friend KE; Hauptman PJ; Peri A; Sigal SH
Kidney Int; 2015 Jul; 88(1):167-77. PubMed ID: 25671764
[TBL] [Abstract][Full Text] [Related]
8. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
Murphy T; Dhar R; Diringer M
Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Der-Nigoghossian C; Lesch C; Berger K
Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
[TBL] [Abstract][Full Text] [Related]
10. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
Palmer BF; Rock AD; Woodward EJ
Drug Des Devel Ther; 2016; 10():339-51. PubMed ID: 26848258
[TBL] [Abstract][Full Text] [Related]
11. Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia.
Metzger BL; DeVita MV; Michelis MF
Int Urol Nephrol; 2008; 40(3):725-30. PubMed ID: 18363040
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rapid intermittent correction compared with slow continuous correction with hypertonic saline in patients with moderately severe or severe symptomatic hyponatremia: study protocol for a randomized controlled trial (SALSA trial).
Lee A; Jo YH; Kim K; Ahn S; Oh YK; Lee H; Shin J; Chin HJ; Na KY; Lee JB; Baek SH; Kim S
Trials; 2017 Mar; 18(1):147. PubMed ID: 28356136
[TBL] [Abstract][Full Text] [Related]
13. [Etiology, diagnostics and therapy of hyponatremias].
Laczi F
Orv Hetil; 2008 Jul; 149(29):1347-54. PubMed ID: 18617466
[TBL] [Abstract][Full Text] [Related]
14. Clinical review: the use of vaptans in clinical endocrinology.
Peri A
J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
[TBL] [Abstract][Full Text] [Related]
15. Where vaptans do and do not fit in the treatment of hyponatremia.
Jovanovich AJ; Berl T
Kidney Int; 2013 Apr; 83(4):563-7. PubMed ID: 23254896
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
17. Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure.
Sahu R; Balaguru D; Thapar V; Haque I; Pham-Peyton C; Bricker JT
Tex Heart Inst J; 2012; 39(5):724-6. PubMed ID: 23109779
[TBL] [Abstract][Full Text] [Related]
18. [Vasopressin antagonists in treatment of hyponatremia].
Olszewski W; Głuszek J
Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
[TBL] [Abstract][Full Text] [Related]
19. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS
Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963
[TBL] [Abstract][Full Text] [Related]
20. Hyponatremia: a problem-solving approach to clinical cases.
Assadi F
J Nephrol; 2012; 25(4):473-80. PubMed ID: 22307436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]